ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile

 

Regeneron Pharmaceuticals, Inc. 

777 Old Saw Mill River Road

Tarrytown  New York  10591  U.S.A.
Phone: 914-847-7000 Fax: n/a


SEARCH JOBS



Known for its scientific and operational excellence, Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, allergic asthma, and atopic dermatitis.

Visit our website – www.regeneron.com
Check out our openings – www.careers.regeneron


 Key Statistics


Email:
Ownership: Public

Web Site: Regeneron
Employees: 2300+
Symbol: REGN
 



Industry
Biotechnology


Collaborations

Sanofi US 

Bayer Corporation 

Geisinger Health System  Collaboration with Regeneron Genetics Center LLC, wholly-owned subsidiary of Regeneron.

Avalanche Biotechnologies 





 Company News
Regeneron (REGN), ReGen Therapeutics Plc (RGT.L) Eczema Drug Dupilumab Gets {3} Breakthrough Therapy Designation 11/20/2014 5:45:20 AM
Sanofi (SAN.PA) And Regeneron (REGN)'s Alirocumab Ph3 Trials Met Primary Efficacy Endpoint 11/19/2014 7:54:40 AM
Regeneron (REGN) Announces EYLEA (aflibercept) Injection Approved For The Treatment Of Diabetic Macular Edema (DME) In Japan 11/18/2014 1:56:06 PM
Regeneron (REGN)'s Eylea Gets Japanese Nod For Macular Edema 11/18/2014 8:04:16 AM
Patent Fight Between Amgen (AMGN) And Sanofi (SAN.PA)/Regeneron (REGN) Getting Murkier, Says Analyst 11/13/2014 3:00:01 PM
Regeneron (REGN), Sanofi (SAN.PA) Asthma Drug A Potential Blockbuster For Allergies, Says Analyst 11/11/2014 3:16:58 PM
Regeneron (REGN) And Sanofi (SAN.PA) Announce Positive Results From Phase 2b Study Of Dupilumab In Patients With Moderate-To-Severe Asthma 11/11/2014 5:51:44 AM
Regeneron (REGN), Sanofi (SAN.PA)'s Dual-Action Biotech Asthma Drug Performs Well In Key Test 11/11/2014 5:50:39 AM
Regeneron (REGN)'s Earnings Disappoint; Dumps More And More Cash On R&D 11/4/2014 8:42:58 AM
Regeneron (REGN) Announces Upcoming 2014 Investor Conference Presentations 11/4/2014 8:12:58 AM
12345678910...